VYRONPEPTIDES

Back to research

Retatrutide research guide

Retatrutide, also known as LY3437943, is an investigational peptide developed to activate three metabolic hormone receptors simultaneously: GLP-1, GIP and glucagon.

This triple-receptor mechanism has attracted considerable scientific interest because it influences interconnected pathways involved in appetite, glucose regulation, energy expenditure and fat metabolism.

Development status: Investigational compound. Not an approved medicine in New Zealand as of November 2026.


Understanding Retatrutide

Retatrutide is a synthetic, long-acting peptide belonging to a class of investigational medicines known as triple-receptor agonists.

Its structure enables interaction with three receptors involved in metabolic regulation.

GLP-1: Appetite and glucose regulation

Glucagon-like peptide-1 is an incretin hormone involved in the regulation of blood glucose and appetite.

GLP-1 receptor activation can:

GIP: Insulin and metabolic signalling

Glucose-dependent insulinotropic polypeptide is another incretin hormone that influences insulin secretion and metabolic function.

GIP receptor activation can:

Glucagon: Energy expenditure and metabolism

Glucagon is a hormone involved in maintaining energy availability and regulating glucose production.

Glucagon receptor activation may:

The glucagon component distinguishes retatrutide from currently established single- and dual-incretin therapies.

Why Triple-Receptor Activation Matters

Body-weight regulation involves multiple interacting biological systems rather than a single hormonal pathway.

Retatrutide is designed to influence three of these systems simultaneously.

Its scientific significance lies in the possibility of combining appetite regulation, insulin signalling and energy expenditure within one molecule.

This approach is being investigated for obesity, type 2 diabetes and other metabolic conditions.

Although results have been encouraging, activation of additional receptors does not automatically guarantee better outcomes or fewer adverse effects for every individual.


Clinical Research and Published Results

Phase 2 Obesity Trial (2023)

A randomised clinical trial published in the New England Journal of Medicine investigated retatrutide in 338 adults with obesity or overweight and a weight-related condition.

At 48 weeks, the highest studied dose group achieved an average body-weight reduction of 24.2%.

The placebo group had an estimated mean reduction of 2.1% at 48 weeks. The trial’s primary endpoint was at 24 weeks.

Phase 3 TRIUMPH-1 (2026)

The Phase 3 TRIUMPH-1 trial compared retatrutide with placebo over 80 weeks in adults with obesity without diabetes. The published paper reports weight changes under different analysis assumptions. The treatment-regimen analysis accounts for participants regardless of whether they continued their assigned treatment. See the Phase 3 paper below for results by group and adverse events.

Type 2 Diabetes Research

Research involving adults with type 2 diabetes has investigated retatrutide's effects on HbA1c, body weight and other metabolic indicators.

In the published Phase 3 TRIUMPH-2 trial, the largest estimated difference in body-weight change was 13.8 percentage points versus placebo at 80 weeks (95% confidence interval 11.8 to 15.8 percentage points). The trial also evaluated changes in HbA1c, a measure of average blood glucose.

Liver Fat Research

A 2024 Phase 2a study investigated retatrutide in participants with metabolic dysfunction-associated steatotic liver disease (MASLD).

The study reported substantial reductions in liver fat content, including estimated relative reductions exceeding 80% in two study groups at 24 weeks, compared with a 0.3% increase in the placebo group. This was a measure of liver fat on imaging.

These results support further investigation of retatrutide's effects beyond body-weight regulation.


Retatrutide Compared with Other Incretin Therapies

Characteristic Semaglutide Tirzepatide Retatrutide
GLP-1 activation Yes Yes Yes
GIP activation No Yes Yes
Glucagon activation No No Yes
Mechanism Single agonist Dual agonist Triple agonist
Clinical status Approved for specified uses Approved for specified uses Investigational

Retatrutide's triple-receptor mechanism offers an additional biological pathway compared with semaglutide and tirzepatide.

However, results from different clinical trials cannot establish definitive superiority. Direct comparative studies are required to assess relative efficacy and safety.


Pharmacological Characteristics

Compound: Retatrutide

Development identifier: LY3437943

Compound class: Synthetic peptide, triple-receptor agonist

Primary receptor targets: GIP, GLP-1 and glucagon

Molecular design: Long-acting acylated peptide

Approximate half-life: Six days, based on clinical pharmacokinetic research

Research areas: Obesity, glucose regulation, energy metabolism, liver fat and cardiometabolic health

Regulatory status: Investigational, with no general approval for clinical use in New Zealand as of November 2026


Safety and Tolerability

Clinical trials have identified gastrointestinal adverse events as the most commonly reported treatment-related problems.

These include:

The Phase 2 obesity trial also reported increases in heart rate. Further research is needed to assess long-term safety and changes in body composition.

Adverse events may vary according to treatment exposure, clinical characteristics and study protocol.

The long-term safety profile continues to be investigated.

Importantly, the safety observations from regulated clinical trials cannot be transferred to independently manufactured or unapproved research products.


Frequently Asked Questions

What is retatrutide?

Retatrutide is an investigational synthetic peptide designed to activate GLP-1, GIP and glucagon receptors simultaneously.

How is retatrutide different from Ozempic?

Ozempic contains semaglutide, which acts on GLP-1 receptors. Retatrutide also activates GIP and glucagon receptors.

How is retatrutide different from tirzepatide?

Tirzepatide activates GLP-1 and GIP receptors. Retatrutide additionally activates the glucagon receptor.

What does triple agonist mean?

A triple agonist is a compound capable of activating three distinct receptor systems.

What weight-loss results have clinical trials reported?

The 2023 Phase 2 obesity trial reported mean weight reduction of up to 24.2% at 48 weeks. The Phase 3 trial followed participants for 80 weeks. Its published results explain how estimates change with the analysis used.

These are clinical trial averages, not guaranteed individual results.

Does retatrutide influence blood glucose?

Yes. Clinical research has demonstrated improvements in glycaemic measures, including HbA1c, in participants with type 2 diabetes.

Does retatrutide increase energy expenditure?

Glucagon receptor activation provides a biological basis for investigating increased energy expenditure. The contribution of this mechanism to clinical outcomes continues to be studied.

Does retatrutide affect liver fat?

Clinical research has reported substantial reductions in liver fat in selected participants. Further investigation is needed to establish long-term clinical benefits.

Does retatrutide cause nausea?

Nausea and other gastrointestinal adverse events have been commonly reported in clinical trials.

Can retatrutide affect heart rate?

Heart-rate changes have been observed in clinical investigations. Cardiovascular safety remains an important area of ongoing research.

Can retatrutide cause muscle loss?

Substantial weight reduction can include reductions in lean mass. Clinical research evaluates body composition alongside overall weight change.

Is retatrutide safe during pregnancy?

There is insufficient evidence to establish safety during pregnancy or breastfeeding. It should not be used outside authorised clinical or medical pathways.

Can retatrutide be combined with semaglutide or tirzepatide?

The safety and efficacy of combining these therapies have not been established. Such combinations should not be attempted independently.

What happens after retatrutide treatment stops?

Long-term weight maintenance after discontinuation remains under investigation. Weight regain is an established concern following discontinuation of several obesity pharmacotherapies, but specific retatrutide outcomes should not be assumed from other medicines.

Is retatrutide approved in New Zealand?

No. As of November 2026, retatrutide remains investigational and has not received general approval for therapeutic use in New Zealand.


Understanding Certificates of Analysis

A Certificate of Analysis (COA) can provide analytical information about a specific tested sample.

Depending on the testing performed, a COA may report:

However, a purity percentage alone does not establish pharmaceutical quality.

A COA does not automatically demonstrate sterility, absence of endotoxins, accurate dosing across all vials or suitability for human administration.

Independent analytical results should always be interpreted according to the tests actually performed and the specific sample examined.


Scientific References

Obesity, Phase 2

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023.

Read the paper

Type 2 Diabetes, Phase 2

Rosenstock J et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes. The Lancet. 2023.

Read the paper

Metabolic Liver Disease

Loomba R et al. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. Nature Medicine. 2024.

Read the paper

Obesity, Phase 3

Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026.

Read the paper


Type 2 Diabetes, Phase 3

Read the published TRIUMPH-2 trial

New Zealand guidance

Read Medsafe’s November 2026 safety alert

About this guide

This material is provided for general scientific and educational information.

Retatrutide is an investigational compound and is not approved for general therapeutic use in New Zealand.

Clinical findings described here relate to regulated pharmaceutical research and should not be interpreted as evidence of the safety, quality or efficacy of independently supplied peptide products.

This information does not constitute medical advice, prescribing guidance, instructions for injection or authorisation to import, supply or use an unapproved medicine.

Any legitimate research activity involving retatrutide must comply with applicable New Zealand legislation, institutional requirements and relevant regulatory approvals.

Information current to November 2026. Scientific and regulatory developments may change.